At page 74, line 24, after "GCGYGRGDSPG" insert --(SEQ ID NO: 61)--. At page 74, line 25, after "GRGDSPG" insert --(SEQ ID NO: 74)--. At page 75, line 8, after "GCGYGRGDSPG" insert --(SEQ ID NO: 61)--. At page 75, line 9, after "GCGYGRGDSPG" insert --(SEQ ID NO: 61)--. At page 75, line 14, after "GCGYGRGDSPG" insert --(SEQ ID NO: 61)--. At page 76, line 22, after "GCGYGRGDSPG" insert --(SEQ ID NO: 61)--. At page 76, line 23, after "GCGYGRGDSPG" insert --(SEQ ID NO: 61)--. At page 76, line 23, after "GCYdKNdRDCG" insert --(SEQ ID NO: 68)--. At page 77, line 22, after "GCYKNRDCG" insert --(SEQ ID NO: 58)--. At page 81, line 23, "(GCYKNRDCG)" insert --(SEQ ID NO: 58)--. At page 83, line 2, after "SH-XXXXY-drug" insert --(SEQ ID NO: 72)--. At page 83, line 14, after "SH-XXXXY-drug" insert --(SEQ ID NO: 72)--. At page 83, line 22, after "GCGYGRGDSPG" insert --(SEQ ID NO: 72)--. At page 83, line 22, after "GCGYGRGDSPG" insert --(SEQ ID NO: 72)--.

## **REMARKS**

The specification has been amended to provide sequence identification numbers for each amino acid sequence or nucleic acid sequence within the specification. No new matter is added by these amendments.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Reg. No. 39,109

Clark & Elbing LLP

176 Federal Street

Boston, MA 02110-2214 Telephone: 617-428-0200

Facsimile: 617-428-7045

\\NTSERVER\checklists\MS Word Versions\PTO Forms\Reply to Examiner's Action.dot